DoD Duchenne Muscular Dystrophy, Translational Research Award | W81XWH 22 DMDRP TRA

Opportunity Information: Apply for W81XWH 22 DMDRP TRA

The DoD Duchenne Muscular Dystrophy, Translational Research Award (FY22 DMDRP TRA) is a Department of Defense funding opportunity designed to push Duchenne muscular dystrophy (DMD) research past the basic science stage and closer to real-world clinical use. The core intent is to support translational research, meaning projects that deliberately connect laboratory discoveries with clinical observations and patient-focused insights. Rather than treating translation as a simple one-direction path from bench to bedside, the program expects an ongoing, two-way exchange where clinical needs and patient data shape the lab work, and lab findings in turn guide clinical strategy. The overall emphasis is on moving a promising concept, therapeutic approach, device, or intervention toward practical clinical application with a near-term impact.

This mechanism is aimed at established projects that already have momentum and are no longer purely exploratory. Applications must include preliminary data that is directly relevant to DMD and to the specific approach being proposed, which signals that the program is not intended for early speculative ideas without supporting evidence. The opportunity explicitly encourages research on therapies that can work across the lifespan, with particular interest in approaches that address the needs of adolescents and adults, populations that have historically had fewer tailored therapeutic options in DMD. The program allows pilot and proof-of-principle clinical trials, along with correlative studies that can clarify how and why a therapy works, identify biomarkers, refine patient selection, or otherwise strengthen the development pathway for drugs, devices, or other interventions.

A key requirement is that the proposed work be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public. While DMD is not limited to military populations, the grant’s framing reflects the DoD’s mission by requiring applicants to clearly explain public and military relevance and potential benefit. The funding instrument types include both grants and cooperative agreements, indicating that some awards may involve more substantial involvement or oversight by the sponsoring agency depending on the project structure.

The FY22 TRA also includes an Early-Career Partnering PI Option to promote meaningful collaboration and strengthen the research pipeline in the DMD field. Under this option, two principal investigators can be formally integrated into the application: an Initiating PI who manages most submission and administrative responsibilities, and an Early-Career Partnering PI who plays a substantive scientific role. The expectation is that both investigators contribute significantly to the design and execution of the study, including major components like the project narrative and statement of work. If funded, each PI is recognized on a separate award under the recipient organization, reinforcing that the partnership is intended to be real and professionally meaningful rather than symbolic.

Administratively, the opportunity is listed under Funding Opportunity Number W81XWH-22-DMDRP-TRA, administered by the Department of Defense (Department of the Army, USAMRAA), with CFDA number 12.420. Eligibility is described as unrestricted, meaning a wide range of organizations may apply as long as they meet any additional conditions in the full announcement. The opportunity was created June 6, 2022, with an original closing date of November 15, 2022, and it anticipated making about two awards. The award ceiling is shown as 0 in the source data, which typically means applicants need to rely on the full announcement for budget limits or that the ceiling is not specified in that summary field.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Duchenne Muscular Dystrophy, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 06, 2022.
• Applicants must submit their applications by Nov 15, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 DMDRP TRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: